Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

d the business combination with Transave on December 1, 2010.  The improved return on investments reflected the increased cash position and higher yield rates, while the lower interest expense was due to the elimination of the debt discount amortization.

As of December 31, 2010, Insmed had total cash, cash equivalents, short-term investments, and certificate of deposits on hand of $110.2 million, consisting of $108.0 million in cash and short-term investments and $2.2 million in a certificate of deposit, as compared to $124.3 million of cash on hand as of December 31, 2009.  The $14.1 million decrease in total cash was due to the $8.0 million full payment of Transave debt at the time of the merger, together with the payment of approximately $6.1 million in costs primarily related to the strategic review during 2010 and the business combination with Transave.

Conference CallTo participate in today's live conference call, please dial 866-543-6405 (U.S. callers) or 617-213-8897 (international), and provide passcode 84436520.  A live webcast of the call will also be available at: http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=3766623.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.  The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on March 10th 2011, at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 46156189.

About InsmedInsmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with unmet medical need. Insmed's primary focus is on the development of inhaled
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Insmed to Host Second Quarter 2009 Conference Call
2. Insmed Announces Addition to the Russell 3000(R) Index
3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
4. Insmed CEO Resigns Due to Health Concerns
5. Insmed Announces First Quarter 2009 Financial Results
6. Insmed Regains NASDAQ Compliance
7. Insmed to Host First Quarter 2009 Conference Call
8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan ... lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup ... prizes of US$15,000 and a period of expert mentorship from a senior industry figure ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... PCR system, developed for,highfidelity PCR , , Kirk ... Daniel McMullan,* Barbara McGowan * Holly Hogrefe ,Stratagene Cloning ... the TaqPlus Precision PCR system,* to an expanding line ... a novel mixture of Taq2000 and Pfu DNA polymerases ...
... tools for neuroscience researchers , , Robert ... Browning, Mary Ellen Simcox ,Stratagene Cloning Systems, Inc. ... sets for the rat and human,NMDA receptor. In ... reverse,transcriptase-mediated polymerase chain reaction (RT-PCR) assays to show,expression ...
... ,Over 40% of Stratagenes GeneConnection cDNA gene clusters are ... full-length clones , Jason Goncalves Jean-Michel Lelias ... clone collection YY ,goes beyond normal ... tissues and has identified thousands of cDNAs that are ...
Cached Biology Technology:High-Fidelity PCR with a Novel Polymerase Mixture 2High-Fidelity PCR with a Novel Polymerase Mixture 3High-Fidelity PCR with a Novel Polymerase Mixture 4High-Fidelity PCR with a Novel Polymerase Mixture 5High-Fidelity PCR with a Novel Polymerase Mixture 6High-Fidelity PCR with a Novel Polymerase Mixture 7High-Fidelity PCR with a Novel Polymerase Mixture 8High-Fidelity PCR with a Novel Polymerase Mixture 9High-Fidelity PCR with a Novel Polymerase Mixture 10High-Fidelity PCR with a Novel Polymerase Mixture 11Gene-Specific Primers for NMDA Receptor Subunits 2Gene-Specific Primers for NMDA Receptor Subunits 3Gene-Specific Primers for NMDA Receptor Subunits 4The GeneZoo or the GeneJungle? 2The GeneZoo or the GeneJungle? 3The GeneZoo or the GeneJungle? 4The GeneZoo or the GeneJungle? 5The GeneZoo or the GeneJungle? 6The GeneZoo or the GeneJungle? 7The GeneZoo or the GeneJungle? 8The GeneZoo or the GeneJungle? 9The GeneZoo or the GeneJungle? 10
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market announces that its Wocket® smart wallet will be the ... scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive one ... Inc.,s CEO Gino Pereira will be discussing its ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... University scientists have unveiled a revolutionary new technology that ... The new "solar steam" method from Rice,s Laboratory for ... steam from icy cold water. Details of the ... ACS Nano . The technology has an overall energy ...
... 2012 (Toronto) - The Centre for Addiction and ... psychiatrist Dr. Aristotle Voineskos, Koerner New Scientist and head ... the Campbell Family Mental Health Research Institute, has been ... Prize for university research in Ontario. The Polanyi ...
... of light to a chunk of gray matter smaller than ... and engineers at the Massachusetts Institute of Technology (MIT) in ... of light to a 3-D section of living brain tissue. ... but promising technique that uses gene therapy to turn individual ...
Cached Biology News:Rice unveils super-efficient solar-energy technology 2Rice unveils super-efficient solar-energy technology 3CAMH scientist wins Polanyi Prize 2A 3-D light switch for the brain 2A 3-D light switch for the brain 3A 3-D light switch for the brain 4
... Caliper is proud to work in collaboration ... Certified 25mm syringe filters in a variety ... are licensed for use on the Caliper ... Specifications and Pricing for our Automation Certified ...
The Microseal 384 plate positioner ensures precise positioning of Microseal 384-well plates in the x-, y-, and z-dimensions, for accurate automated liquid handling....
... Thermo-Sealer is a manual heat sealer ideal for ... portable instrument can seal a wide range of ... carriers. The heating element of the sealer is ... or peelable seals when used in conjunction with ...
...
Biology Products: